Video

CIRSE 23: ZILVERPASS: ZILVER PTX Stent Vs Bypass Surgery in Fem-pop Lesions

Published: 26 Sep 2023

  • Views:

    Views Icon 90
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

CIRSE 23 - Dr Michel Boisiers (Inselspital Bern, CH) shares the 5-year outcomes of the ZILVERPASS study in this succinct interview.

The ZILVERPASS study aimed to evaluate the outcomes of the Zilver PTX paclitaxel-eluting stent (Cook) as compared to bypass surgery in the treatment of TASC C&D femoropoliteal lesions. 

220 patients were enrolled in the study, and were randomized to receive either intervention with the Zilver PTX device, or a prosthetic bypass graft according to standard of care. 

Questions:

1. What is the rationale behind this trial?
2. What was the patient cohort and study design?
3. What were the early and mid-term outcomes?
4. What are the five-year results?
6. What are your take-home messages from this study?
7. What further research is still required?

Recorded remotely from Bern, 2023.

Editor: Jordan Rance
Video Specialist: Oliver Miles

Comments

You must be to comment. If you are not registered, you can register here.